SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is experiencing a surge in interest, with community members attributing the recent price action to upcoming satellite launches and potential government contracts. Community members are actively discussing technical analysis points, institutional investment, and the potential for ASTS to disrupt the telecom industry. Some traders express caution, referencing the company's history of missed deadlines and the broader economic climate.

Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

Q/C Technologies Inc.

Q/C Technologies is trending following news that Martin Shkreli has taken a position in the company and set a near-term price target of $100, sparking considerable discussion among investors. The community is actively discussing the potential of the company's technology and the implications of Shkreli's involvement, with some expressing skepticism and others anticipating a significant price increase. High trading volume and recent price action suggest heightened interest in QCLS within the next-generation computing sector.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath ($PATH) is trending amid discussions of its earnings report, where annualized recurring revenue increased, and the CEO highlighted the company's AI automation strategy. The community is focused on the potential for a short squeeze and positive long-term outlook, with some discussing potential price targets for 2026. Recent partnerships and analyst ratings are also key talking points.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MLTX is trending as the community anticipates upcoming catalysts, including a Type B meeting with the FDA on December 15th regarding its lead drug candidate, sonelokimab (SLK).  Optimism stems from the drug's potential in treating inflammatory and autoimmune diseases, as well as speculation around a possible buyout from a major pharmaceutical company.  Despite recent clinical trial setbacks and shareholder lawsuits, investors are closely watching for positive news that could significantly impact the stock's valuation.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VKTX is trending amid community speculation regarding potential catalysts, including an FDA meeting and buyout rumors, driving high volumes and short covering. Community members are actively discussing the possibility of a streamlined Phase 3 trial for oral VK2735 and potential acquisition offers from major pharmaceutical companies seeking to bolster their GLP-1 portfolios.  The stock's movement is further fueled by discussions around the competitive landscape within the weight loss and metabolic disease sector.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

CADL is trending as investors discuss its potential for a buyout or strategic partnership, fueled by promising data in lung, prostate, and pancreatic cancers. Community talking points center on the company being significantly undervalued with a large short interest, positioning it for a potential squeeze. The discussion is around CADL's pipeline and proximity to BLA filing, which could increase its attractiveness in the biotech sector.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is trending following its recent earnings report, with community discussions focused on whether the results justify the stock's muted reaction and long-term potential. Despite an earnings beat and raised guidance, some express concern over revenue and the company's positioning in the competitive AI landscape. Analysts are weighing in with updated ratings and price targets, adding to the debate around CRM's future performance.

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Bozeman, MT.

Snowflake Inc

Snowflake is trending amid a mix of bullish analyst upgrades and some community concern regarding slower product revenue growth forecasts. Some traders are pointing to insider selling and margin shrinkage as reasons to be bearish, while others see recent partnerships with Palantir and Anthropic, and growing AI adoption, as positive catalysts. Overall, the discussion revolves around valuation and whether Snowflake can maintain its high growth trajectory.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Tonix Pharmaceuticals Holding Corp

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

AI is trending due to a U.S. Department of Health and Human Services contract win, with community members seeing this as a potential catalyst for a short squeeze given the stock's high short interest. Bullish sentiment is building around the new CEO and potential for government deals, while some are comparing it unfavorably to competitors and citing concerns around revenue and profitability. Overall, the conversation is centered on whether this news can spark a turnaround for the heavily shorted AI stock.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$CPRT Conflicting (Sell/Negative) Signals 
Despite the technical buy signals, several other metrics indicate caution: 
Overall Technical Rating: Based on a wider range of technical indicators, some analyses still rate CPRT as an overall &quot;Sell&quot; or &quot;Strong Sell&quot;. 
Moving Averages: The stock is currently trading below its 20-day, 50-day, and 200-day moving averages, which generally indicates a negative forecast in the short and long term. 
Falling Trend: The stock is within a falling short-term trend, and is expected to fall further over the next three months according to some forecasts. 
Insider Activity: There has been significant open-market selling from key executives and directors recently, which can be a negative signal to potential investors. 
Analyst Consensus: The overall consensus rating from Wall Street analysts is generally a &quot;Hold,&quot; with an average price target that suggests potential upside, but not an immediate strong consensus to buy.